PDF(Pubmed)
Abstract：
Artificial tears are the mainstay of dry eye disease management, but also have a role in corneal abrasion and wound healing, pain and inflammation management, conjunctivitis, keratitis, contact lens rewetting and removal, and foreign body removal. A systematic review of randomized controlled trials (PROSPERO registration CRD42022369619) comparing the efficacy of artificial tears in patients with dry eye to inform prescribing choices using Web of Science, PubMed and Medline databases identified 64 relevant articles. There is good evidence that artificial tears improve symptoms of dry eye disease within a month of regular use, applied about four times a day, but signs generally take several months to improve. Not all patients with dry eye disease benefit from artificial tears, so if there is no benefit over a month, alternative management should be considered. Combination formulations are more effective than single active ingredient artificial tears. Artificial tears containing polyethylene glycol are more effective than those containing carboxymethylcellulose/carmellose sodium and hydroxypropyl methylcellulose. Those classified as having evaporative dry eye disease, benefit from artificial tears with liposomes, especially of higher concentration. The data available is limited by the definition of dry eye disease applied in published studies being variable, as well as the disease severity examined and compliance with artificial tears being rarely quantified.
摘要：
人工泪液是干眼症管理的主体,而且在角膜磨损和伤口愈合中也有作用，疼痛和炎症管理，结膜炎,角膜炎,隐形眼镜的再润湿和移除，和异物去除。系统评价随机对照试验（PROSPERO注册CRD420223669619），比较人工泪液在干眼症患者中的疗效，以告知使用WebofScience的处方选择，PubMed和Medline数据库确定了64篇相关文章。有很好的证据表明，人工泪液在经常使用一个月内改善干眼症的症状，每天申请四次，但是症状通常需要几个月才能改善。并非所有干眼症患者都能从人工泪液中受益，所以如果一个月以上没有好处，应该考虑替代管理。组合制剂比单一活性成分人工泪液更有效。含有聚乙二醇的人工泪液比含有羧甲基纤维素/羧甲基纤维素钠和羟丙基甲基纤维素的人工泪液更有效。那些被归类为蒸发性干眼病的人，受益于脂质体人工泪液，特别是浓度较高。现有的数据受到已发表研究中应用的干眼症定义的限制，以及检查的疾病严重程度和对人工泪液的依从性很少量化。
